|
Name |
Ethyl 5-oxohexanoate
|
Molecular Formula | C8H14O3 | |
IUPAC Name* |
ethyl 5-oxohexanoate
|
|
SMILES |
CCOC(=O)CCCC(=O)C
|
|
InChI |
InChI=1S/C8H14O3/c1-3-11-8(10)6-4-5-7(2)9/h3-6H2,1-2H3
|
|
InChIKey |
MGPSIDGTLFKDEY-UHFFFAOYSA-N
|
|
Synonyms |
Ethyl 5-oxohexanoate; Ethyl 4-acetylbutyrate; 13984-57-1; Hexanoic acid, 5-oxo-, ethyl ester; 5-Oxohexanoic acid ethyl ester; DJ9EME6QBQ; MFCD00009213; Ethyl 4-acetylbutanoate; EINECS 237-776-7; UNII-DJ9EME6QBQ; ethyl 4-acetyl-butanoate; ETHYL4-ACETYLBUTYRATE; SCHEMBL723390; Ethyl 4-acetylbutyrate, 98%; 5-oxo-hexanoic acid ethyl ester; DTXSID6065688; MGPSIDGTLFKDEY-UHFFFAOYSA-; ZINC2534768; BBL027744; STL373437; AKOS015915557; CS-W010896; AS-44005; SY033235; DB-042489; FT-0626069; EN300-105271; A885944; J-800372; BKN
|
|
CAS | 13984-57-1 | |
PubChem CID | 84130 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 158.19 | ALogp: | 0.4 |
HBD: | 0 | HBA: | 3 |
Rotatable Bonds: | 6 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 43.4 | Aromatic Rings: | 0 |
Heavy Atoms: | 11 | QED Weighted: | 0.573 |
Caco-2 Permeability: | -4.406 | MDCK Permeability: | 0.00003570 |
Pgp-inhibitor: | 0.343 | Pgp-substrate: | 0.003 |
Human Intestinal Absorption (HIA): | 0.003 | 20% Bioavailability (F20%): | 0.01 |
30% Bioavailability (F30%): | 0.356 |
Blood-Brain-Barrier Penetration (BBB): | 0.995 | Plasma Protein Binding (PPB): | 41.67% |
Volume Distribution (VD): | 0.417 | Fu: | 71.22% |
CYP1A2-inhibitor: | 0.722 | CYP1A2-substrate: | 0.625 |
CYP2C19-inhibitor: | 0.394 | CYP2C19-substrate: | 0.715 |
CYP2C9-inhibitor: | 0.08 | CYP2C9-substrate: | 0.751 |
CYP2D6-inhibitor: | 0.021 | CYP2D6-substrate: | 0.39 |
CYP3A4-inhibitor: | 0.02 | CYP3A4-substrate: | 0.255 |
Clearance (CL): | 9.052 | Half-life (T1/2): | 0.92 |
hERG Blockers: | 0.034 | Human Hepatotoxicity (H-HT): | 0.04 |
Drug-inuced Liver Injury (DILI): | 0.133 | AMES Toxicity: | 0.01 |
Rat Oral Acute Toxicity: | 0.007 | Maximum Recommended Daily Dose: | 0.031 |
Skin Sensitization: | 0.236 | Carcinogencity: | 0.051 |
Eye Corrosion: | 0.963 | Eye Irritation: | 0.968 |
Respiratory Toxicity: | 0.025 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001036 | 0.611 | D0AY9Q | 0.365 | ||||
ENC000371 | 0.606 | D0OL6O | 0.341 | ||||
ENC001015 | 0.526 | D0K3LW | 0.295 | ||||
ENC000226 | 0.515 | D0Q7ZQ | 0.286 | ||||
ENC000516 | 0.489 | D0Y4AW | 0.283 | ||||
ENC000250 | 0.471 | D0G2KD | 0.282 | ||||
ENC000410 | 0.441 | D05PHH | 0.274 | ||||
ENC000254 | 0.432 | D0Y7ZD | 0.268 | ||||
ENC000224 | 0.424 | D0O4GY | 0.262 | ||||
ENC000248 | 0.417 | D0G2MW | 0.256 |